APPLICATION
ANDA202032
TYPE
ANDA
ORIGINAL APPROVAL
2011-11-17
LATEST ACTION
2019-09-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
LAMIVUDINEDiscontinued
LAMIVUDINE 300MG · TABLET · ORAL
LAMIVUDINEDiscontinued
LAMIVUDINE 150MG · TABLET · ORAL
Approval history
2019-09-24Labeling · Supplement 8 · standardAP
2019-09-24Labeling · Supplement 6 · standardAP
2019-09-24Labeling · Supplement 10 · standardAP
2019-09-24Labeling · Supplement 7 · standardAP
2019-09-24Labeling · Supplement 13 · standardAP
2019-09-24Labeling · Supplement 11 · standardAP
2012-03-31Labeling · Supplement 1AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.